To evaluate the cost-effectiveness analysis of nintedanib esylate in the treatment of idiopathic pulmonary fibrosis (IPF).
From the perspective of Chinese healthcare system, a Markov model was constructed to evaluate the cost-effectiveness of nintedanib esylate compared with pirfenidone in the treatment of IPF patients. The model cycle was one month using a lifetime horizon. The discount rate of both cost and effectiveness was 5%. One-way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis were used to verify the robustness of the base case results.
The results of the base case showed that compared with generic pirfenidone, nintedanib esylate had lower costs and higher quality-adjusted life years output in the treatment of IPF patients, which had absolute advantages and was a more economical program. The conclusion was verified in one-way sensitivity analysis, probabilistic sensitivity analysis and scenario analysis.
Nintedanib esylate is a cost-effective alternative compared with generic pirfenidone in Chinese patients with IPF.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |